{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypothyroidism/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field be1dc943-8714-4172-8426-d4f28a751e8d --><h2>What is the prognosis?</h2><!-- end field be1dc943-8714-4172-8426-d4f28a751e8d -->","summary":"","htmlStringContent":"<!-- begin item a3675815-b422-46bb-ae63-d7422815bd54 --><!-- begin field 025e642c-1aaa-4724-8719-9612098e5091 --><ul><li><strong>Primary hypothyroidism</strong><ul><li>This usually has a good prognosis, and most people will recover full physical and psychological wellbeing following adequate thyroid hormone replacement with levothyroxine (LT4), which is usually needed for life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>]. </li><li>About 5–10% of people have persistent symptoms (such as impaired wellbeing and cognitive disturbance) after 6 months of thyroid hormone treatment, even when thyroid function tests have normalized [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Wiersinga et al, 2012</a>].</li><li>Spontaneous remission is rare [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>].</li></ul></li><li><strong>Subclinical hypothyroidism (SCH)</strong><ul><li>The European Thyroid Association (ETA) guideline states that thyroid function may normalize in 6–35% of people with untreated subclinical hypothyroidism, depending on initial thyroid-stimulating hormone (TSH) levels, thyroid autoantibody status, and length and frequency of follow-up [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>].<ul><li>A large retrospective, observational study (n = 346,549) found that 62.1% of people with TSH levels between 5.5 and 10 mU/L had normal TSH levels on repeat testing without treatment within five years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Meyerovitch, 2007</a>].</li></ul></li><li>The risk of progression to overt hypothyroidism is between 2–5% a year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Vanderpump et al, 1995</a>].<ul><li>Higher serum TSH levels (especially greater than 10 mU/L), positive thyroid autoantibodies, and female sex increase the risk of disease progression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Cooper and Biondi, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">LeFevre, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>].</li></ul></li><li>The annual rate of progression from subclinical hypothyroidism to overt hypothyroidism has been estimated at about 4% in women with raised TSH and positive thyroid autoantibodies; 2–4% in those with raised TSH alone; and 1–3% in those with thyroid autoantibodies alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Cooper and Biondi, 2012</a>].</li></ul></li><li><strong>Postpartum thyroiditis (PPT)</strong><ul><li>The clinical course of PPT varies, with about 25% of women presenting with the classical form (transient thyrotoxicosis followed by transient hypothyroidism followed by a return to the euthyroid state); 25% have isolated thyrotoxicosis; and about 50% present with isolated hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>PPT usually resolves spontaneously within one year of giving birth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>Women with a history of PPT have a markedly increased risk of developing permanent primary hypothyroidism in the 5–10 year period after the episode of PPT [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>].</li><li>A minority of women do not recover from the initial hypothyroid phase of PPT, and 10–50% of women where the initial hypothyroid phase has resolved will go on to develop permanent hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>Women who fully recover from PPT have a 70% chance of developing PPT in each subsequent pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li></ul></li></ul><!-- end field 025e642c-1aaa-4724-8719-9612098e5091 --><!-- end item a3675815-b422-46bb-ae63-d7422815bd54 -->","topic":{"id":"f1d76bc1-c8dd-515b-a709-48c70c829658","topicId":"ebfc5032-6653-4b11-895c-5080f933e861","topicName":"Hypothyroidism","slug":"hypothyroidism","lastRevised":"Last revised in August 2020","chapters":[{"id":"cf0a606b-f582-5671-a84d-a1a3a12b7180","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"795eb9d9-4e15-51f6-81f4-7cc1b69ca74e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8d7a846-dfa6-5db5-ba95-fb161fd48c6e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d8567cc1-0642-5e9e-ad6c-8ca4abf5fa6e","slug":"changes","fullItemName":"Changes"},{"id":"c5e99cd1-e0c7-5efd-84bb-15bac6122b1d","slug":"update","fullItemName":"Update"}]},{"id":"2b8464ae-3182-517a-85be-6acc656616c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"17d5ebf3-bdca-50d2-a4f5-245d191f4973","slug":"goals","fullItemName":"Goals"},{"id":"9162c6a3-edc4-5319-9418-04b2cb656ce6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ae5c1d9-638e-52fa-b738-9561cd11b0ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fec82ae-e144-56a7-b1e8-8744c35e227e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"610f052f-83a2-5b06-b5e6-4aa272ef73a6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a578bde3-0d84-54f7-814d-18ed38e6038a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4b8f382f-673d-5804-8291-438e21e32790","slug":"definition","fullItemName":"Definition"},{"id":"ef0d96cd-207c-5814-93cf-c96870e2251d","slug":"causes","fullItemName":"Causes"},{"id":"09adb285-1d01-592a-9443-295b45c7d78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications"},{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cfe582c4-479a-5d44-b893-ac46a1a80b29","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6884c3db-6165-566b-a4ca-3e933de77714","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"42799fb8-7252-541e-9af1-27ebc28710b7","slug":"assessment","fullItemName":"Assessment"},{"id":"e850b740-b6cf-55a7-aed8-7372b7f13b05","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"d817ab4c-e7a3-582a-94fa-fcffd9c2d4f6","slug":"screening","fullItemName":"Screening"}]},{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","fullItemName":"Management","slug":"management","subChapters":[{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)"},{"id":"e358d249-a2f3-5a06-b301-2119af9ae164","slug":"subclinical-hypothyroidism-non-pregnant","fullItemName":"Scenario: Subclinical hypothyroidism (non-pregnant)"},{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant"},{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum"}]},{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine"}]},{"id":"2aaf1754-ba79-5b47-b2a5-74fe8f6af4da","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7669c894-3a85-55c7-b689-cb4b710a838a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"840d7de5-8c31-5696-9de6-c80ce1bbfec7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"299c20bf-2a22-5681-99ad-5f02f1395969","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd3df39b-4a5c-5416-af8d-dcdbf46bd255","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a88d4431-778a-5793-9557-9f806339a95b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1987302d-f600-55e0-a528-d3486c49048e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a49e5d2f-75e4-5219-a4d6-fd4a5595a776","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}